- Patent Title: Biomarkers for determining the clinical response to cell therapy
-
Application No.: US15568563Application Date: 2016-04-25
-
Publication No.: US10746729B2Publication Date: 2020-08-18
- Inventor: Olga De La Rosa , Wilfried Dalemans
- Applicant: TiGenix, S.A.U.
- Applicant Address: ES Tres Cantos (Madrid)
- Assignee: TIGENIX, S.A.U.
- Current Assignee: TIGENIX, S.A.U.
- Current Assignee Address: ES Tres Cantos (Madrid)
- Agency: Thomas | Horstemeyer, LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5965154a
- International Application: PCT/EP2016/059196 WO 20160425
- International Announcement: WO2016/170187 WO 20161027
- Main IPC: G01N33/50
- IPC: G01N33/50 ; A61K35/28 ; G01N33/68
Abstract:
The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.
Public/Granted literature
- US20180156785A1 BIOMARKERS FOR DETERMINING THE CLINICAL RESPONSE TO CELL THERAPY Public/Granted day:2018-06-07
Information query
IPC分类:
